Perspective Therapeutics (CATX) Competitors $2.24 -0.06 (-2.39%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CATX vs. IRMD, AVNS, BBNX, SIBN, KIDS, OM, TMCI, DCTH, SMLR, and NPCEShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Iradimed (IRMD), Avanos Medical (AVNS), Beta Bionics (BBNX), SI-BONE (SIBN), OrthoPediatrics (KIDS), Outset Medical (OM), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Semler Scientific (SMLR), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Iradimed Avanos Medical Beta Bionics SI-BONE OrthoPediatrics Outset Medical Treace Medical Concepts Delcath Systems Semler Scientific NeuroPace Iradimed (NASDAQ:IRMD) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do analysts rate IRMD or CATX? Iradimed presently has a consensus price target of $72.00, suggesting a potential upside of 37.10%. Perspective Therapeutics has a consensus price target of $14.44, suggesting a potential upside of 543.41%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Perspective Therapeutics is more favorable than Iradimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iradimed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17 Which has higher earnings & valuation, IRMD or CATX? Iradimed has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIradimed$73.24M9.12$19.23M$1.5035.01Perspective Therapeutics$1.43M106.11-$46.51MN/AN/A Which has more volatility & risk, IRMD or CATX? Iradimed has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Does the media refer more to IRMD or CATX? In the previous week, Perspective Therapeutics had 9 more articles in the media than Iradimed. MarketBeat recorded 14 mentions for Perspective Therapeutics and 5 mentions for Iradimed. Iradimed's average media sentiment score of 1.35 beat Perspective Therapeutics' score of -0.16 indicating that Iradimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iradimed 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perspective Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders believe in IRMD or CATX? 92.3% of Iradimed shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 37.1% of Iradimed shares are held by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is IRMD or CATX more profitable? Iradimed has a net margin of 26.26% compared to Perspective Therapeutics' net margin of -4,096.66%. Iradimed's return on equity of 24.12% beat Perspective Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iradimed26.26% 24.12% 21.20% Perspective Therapeutics -4,096.66%-27.40%-23.16% Does the MarketBeat Community favor IRMD or CATX? Iradimed received 228 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 96.88% of users gave Perspective Therapeutics an outperform vote while only 65.40% of users gave Iradimed an outperform vote. CompanyUnderperformOutperformIradimedOutperform Votes25965.40% Underperform Votes13734.60% Perspective TherapeuticsOutperform Votes3196.88% Underperform Votes13.13% SummaryIradimed beats Perspective Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$151.74M$4.37B$5.64B$19.51BDividend YieldN/A32.64%4.57%3.75%P/E RatioN/A28.7223.1633.40Price / Sales106.1150.25384.1426.90Price / CashN/A51.0838.1617.54Price / Book0.846.106.904.56Net Income-$46.51M$67.64M$3.20B$1.02B7 Day Performance-10.91%-3.67%-1.69%-0.38%1 Month Performance-19.24%-2.08%2.68%-3.16%1 Year Performance-81.13%10.75%10.20%4.33% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics2.923 of 5 stars$2.25-2.4%$14.44+543.4%N/A$151.74M$1.43M0.0070Analyst ForecastNews CoverageIRMDIradimed4.8681 of 5 stars$52.86+1.0%$72.00+36.2%+23.1%$672.12M$73.24M35.24110Positive NewsAVNSAvanos Medical2.7185 of 5 stars$14.41-1.8%N/A-28.0%$662.77M$687.80M42.374,040BBNXBeta BionicsN/A$14.85-1.7%$24.83+67.2%N/A$636.46M$53.03M0.00294Earnings ReportAnalyst RevisionNews CoverageSIBNSI-BONE3.9105 of 5 stars$14.82+1.1%$24.50+65.3%-11.6%$629.15M$167.18M-16.11350Short Interest ↑Positive NewsHigh Trading VolumeKIDSOrthoPediatrics4.2252 of 5 stars$24.86-0.4%$37.25+49.8%-14.6%$603.78M$204.73M-20.21200Positive NewsOMOutset Medical1.954 of 5 stars$10.49+4.4%$67.50+543.5%-63.3%$565.38M$113.69M-4.23520Stock SplitShort Interest ↓TMCITreace Medical Concepts2.5709 of 5 stars$8.69+5.3%$10.14+16.7%-32.3%$544.16M$209.36M-8.78250Short Interest ↓Gap UpDCTHDelcath Systems3.2917 of 5 stars$13.96+1.7%$22.75+63.0%+163.3%$466.31M$37.21M-10.3460Positive NewsSMLRSemler Scientific3.5235 of 5 stars$42.88+9.3%$71.00+65.6%+29.3%$411.52M$56.29M8.73120News CoveragePositive NewsNPCENeuroPace2.1942 of 5 stars$12.30+2.3%$15.20+23.6%-9.2%$400.49M$79.91M-12.30170Short Interest ↑Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies IRMD Alternatives AVNS Alternatives BBNX Alternatives SIBN Alternatives KIDS Alternatives OM Alternatives TMCI Alternatives DCTH Alternatives SMLR Alternatives NPCE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CATX Stock Free CATX Stock Alerts